中国临床医生杂志2020年第48卷第5期
527
指南与共识
··
PreventionProgram(DPP):descriptionoflifestyleintervention[J].2010;362(17):1575-1585.
DiabetesCare,2002,25(12):2165-2171.[52]BerlT,HunsickerLG,LewisJB,etal.Impactofachievedblood
[35]AmericanDiabetesAssociation.Preventionordelayoftype2pressureoncardiovascularoutcomesintheIrbesartanDiabetic
diabetes:standardsofmedicalcareindiabetes-2018[J].DiabetesNephropathyTrial[J].JAmSocNephrol,2005,16(7):2170-2179.
Care,2018,41(Suppl1):S51-S54.[53]SudhopT,LutjohannD,KodalA,etal.Inhibitionofintestinal
[36]RejeskiWJ,IpEH,BertoniAG,etal.Lifestylechangeandcholesterolabsorptionbyezetimibeinhumans[J].Circulation,
mobilityinobeseadultswithtype2diabetes[J].NEnglJMed,2002,106(15):1943-1948.
2012,366(13):1209-1217.[54]FriedLF,EmanueleN,ZhangJH,etal.Combinedangiotensin
[37]ColbergSR,SigalRJ,FernhallB,etal.Exerciseandtype2inhibitionforthetreatmentofdiabeticnephropathy[J].NEnglJ
diabetes:theAmericanCollegeofSportsMedicineandtheMed,2013,369(20):1892-1903.
AmericanDiabetesAssociation:jointpositionstatementexecutive[55]ParvingHH,BrennerBM,McMurrayJJ,etal.Cardiorenalend
summary[J].DiabetesCare,2010,33(12):2692-2696.pointsinatrialofaliskirenfortype2diabetes[J].NEnglJMed,
[38]SheehyA,PandhiN,CoursinDB,etal.Minoritystatusand2012,367(23):2204-2213.
diabetesscreeninginanambulatorypopulation[J].DiabetesCare,[56]MyrupB,RossingP,JensenT,etal.Procoagulantactivityand
2011,34(6):1289-1294.intimaldysfunctioninIDDM[J].Diabetologia,1995,38(1):73-78.
[39]BergerM,BerchtoldP,CuppersHJ,etal.Metabolicandhormonal[57]刘玉才,徐飞.前列地尔治疗糖尿病肾病的机制及临床应用[J].
effectsofmuscularexerciseinjuveniletypediabetics[J].Diabetologia,中国老年学杂志,2016,36(02):500-501.
1977,13(4):355-365.[58]祁佳,陈伦,张宇锋.前列地尔联合氯沙坦治疗糖尿病肾病临床
[40]HallanSI,OrthSR.Smokingisariskfactorintheprogressionto疗效的系统评价[J].山东医药,2015,55(28):12-14.
kidneyfailure[J].KidneyInt,2011,80(5):516-523.[59]刘瑛,赵豫梅,张旭祥,宋滇平.羟苯磺酸钙联合前列地尔辅助
[41]DCCT/EDICresearchgroup.Effectofintensivediabetestreatment治疗糖尿病肾病有效性的系统评价[J/CD].中华临床医师杂志
onalbuminuriaintype1diabetes:long-termfollow-upofthe(电子版),2015,9(17):3255-3259.
DiabetesControlandComplicationsTrialandEpidemiology[60]WangH,DengJL,YueJ,etal.ProstaglandinE1forpreventingthe
ofDiabetesInterventionsandComplicationsstudy[J].Lancetprogressionofdiabetickidneydisease[J].CochraneDatabaseSyst
DiabetesEndocrinol,2014,2(10):793-800.Rev,2010(5):Cd006872.
[42]WritingTeamfortheDiabetesControlandComplicationsTrial/[61]LiZC,CaiYZ,TangZG,etal.Lipo-prostaglandinE1improves
EpidemiologyofDiabetesInterventionsandComplicationsrenalhypoxiaevaluatedbyBOLD-MRIinpatientswithdiabetic
ResearchGroup.Sustainedeffectofintensivetreatmentoftypekidneydisease[J].ClinImaging,2018(50):239-242.
1diabetesmellitusondevelopmentandprogressionofdiabetic[62]LiS,WangY,ChenL,etal.Beraprostsodiummitigatesrenal
nephropathy:theEpidemiologyofDiabetesInterventionsandinterstitialfibrosisthroughrepairingrenalmicrovessels[J].JMol
Complications(EDIC)study[J].JAMA,2003,290(16):2159-2167.Med(Berl)，2019，97(6):777–791.
[43]GrayA,RaikouM,McGuireA,etal.Costeffectivenessofan[63]WangXF,ZhangBH,LuXQ,etal.Beraprostsodium,astable
intensivebloodglucosecontrolpolicyinpatientswithtype2analogueofPGI2,inhibitstherenin-angiotensinsysteminthe
diabetes:economicanalysisalongsiderandomisedcontrolledrenaltissuesofratswithchronicrenalfailure[J].KidneyBlood
trial(UKPDS41).UnitedKingdomProspectiveDiabetesStudyPressRes,2018,43(4):1231–1244.
Group[J].BMJ,2000,320(7246):1373-1378.[64]MuskietMHA,TonneijckL,HuangY,etal.Lixisenatideand
[44]GersteinHC,MillerME,ByingtonRP,etal.Effectsofintensiverenaloutcomesinpatientswithtype2diabetesandacutecoronary
glucoseloweringintype2diabetes[J].NEnglJMed,2008,syndrome:anexploratoryanalysisoftheELIXArandomised,placebo-
358(24):2545-2559.controlledtrial[J].LancetDiabetesEndocrinol,2018,6(11):859-869.
[45]vanderLeeuwJ,VisserenFL,WoodwardM,etal.Estimation[65]MannJFE,OrstedDD,Brown-FrandsenK,etal.Liraglutideand
ofindividualbeneficialandadverseeffectsofintensiveglucoserenaloutcomesintype2diabetes[J].NEnglJMed,2017,377(9):
controlforpatientswithtype2diabetes[J].Diabetologia,2016,839-848.
59(12):2603-2612.[66]RosenstockJ,PerkovicV,JohansenOE,etal.Effectoflinagliptin
[46]AgrawalL,AzadN,BahnGD,etal.Long-termfollow-upofintensivevsplaceboonmajorcardiovasculareventsinadultswithtype2
glycaemiccontrolonrenaloutcomesintheVeteransAffairsdiabetesandhighcardiovascularandrenalrisk:TheCARMELINA
DiabetesTrial(VADT)[J].Diabetologia,2018,61(2):295-299.randomizedclinicaltrial[J].JAMA,2019,321(1):69-79.
[47]中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏[67]PetrykivSI,LavermanGD,deZeeuwD,etal.Thealbuminuria-
疾病防治临床指南[J].中华糖尿病杂志,2019,11(1):15-28.loweringresponsetodapagliflozinisvariableandreproducible
[48]LewisEJ,HunsickerLG,BainRP,etal.Theeffectofangiotensin-amongindividualpatients[J].DiabetesObesMetab,2017,19(10):
converting-enzymeinhibitionondiabeticnephropathy.The1363-1370.
CollaborativeStudyGroup[J].NEnglJMed,1993,329(20):1456-[68]WannerC,InzucchiSE,LachinJM,etal.Empagliflozinand
1462.ProgressionofKidneyDiseaseinType2Diabetes[J].NEnglJ
[49]BrennerBM,CooperME,deZeeuwD,etal.EffectsoflosartanonMed,2016,375(4):323-334.
renalandcardiovascularoutcomesinpatientswithtype2diabetes[69]NealB,PerkovicV,MahaffeyKW,etal.Canagliflozinand
andnephropathy[J].NEnglJMed,2001,345(12):861-869.CardiovascularandRenalEventsinType2Diabetes[J].NEnglJ
[50]LewisEJ,HunsickerLG,ClarkeWR,etal.RenoprotectiveeffectMed,2017,377(7):644-657.
oftheangiotensin-receptorantagonistirbesartaninpatientswith[70]PerkovicV,JardineMJ,NealB,etal.CanagliflozinandRenal
nephropathyduetotype2diabetes[J].NEnglJMed,2001,OutcomesinType2DiabetesandNephropathy[J].NEnglJMed,
345(12):851-860.2019,380(24):2295-2306.
[51]CushmanWC,EvansGW,ByingtonRP,etal.Effectsofintensive收稿日期：2020-03-16
blood-pressurecontrolintype2diabetesmellitus[J].NEnglJMed（本文编辑：王丽） |
|
